Robert Delage
YOU?
Author Swipe
View article: Radiotherapeutic Treatment of an Epidermoid Tumor in a Patient With Zanubrutinib-Treated Mantle Cell Lymphoma: The First Report of Concomitant Treatment
Radiotherapeutic Treatment of an Epidermoid Tumor in a Patient With Zanubrutinib-Treated Mantle Cell Lymphoma: The First Report of Concomitant Treatment Open
Mantle cell lymphoma (MCL) is a challenging B-cell non-Hodgkin lymphoma with a poor prognosis and frequent relapses. While treatment advancements such as rituximab and Bruton tyrosine kinase inhibitors (BTKi) like ibrutinib have improved o…
View article: Reduced Intensity transplantation vs chemotherapy. A prospective, pseudorandomized study in 50-70 year old AML patients
Reduced Intensity transplantation vs chemotherapy. A prospective, pseudorandomized study in 50-70 year old AML patients Open
The aim of this prospective, international multicenter, pseudorandomized study using the donor versus no-donor concept to compare RICT HCT to standard-of-care chemotherapy in intermediate- or high risk AML patients 50 – 70 years in CR1. Pa…
View article: A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry
A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry Open
Patients with lower-risk (LR) myelodysplastic syndromes (MDS) with ring sideroblasts (RS) have better prognosis than those without RS, but how they fare over time is not fully understood. This study's objective was to assess the natural hi…
View article: High transferrin saturation predicts inferior clinical outcomes in patients with myelodysplastic syndromes
High transferrin saturation predicts inferior clinical outcomes in patients with myelodysplastic syndromes Open
Iron overload (IO) reflected by elevated ferritin is associated with increased mortality in myelodysplastic syndromes (MDS), however, ferritin is an imperfect metric. Elevated labile plasma iron correlates with clinical outcomes and transf…
View article: S158: FINAL RESULT OF TKI DISCONTINUATION TRIAL WITH DASATINIB FOR SECOND ATTEMPT OF TREATMENT FREE REMISSION AFTER FAILING FIRST ATTEMPT WITH IMATINIB: TREATMENT-FREE REMISSION ACCOMPLISHED BY DASATINIB
S158: FINAL RESULT OF TKI DISCONTINUATION TRIAL WITH DASATINIB FOR SECOND ATTEMPT OF TREATMENT FREE REMISSION AFTER FAILING FIRST ATTEMPT WITH IMATINIB: TREATMENT-FREE REMISSION ACCOMPLISHED BY DASATINIB Open
Background: The Canadian tyrosine kinase inhibitor (TKI) discontinuation (DISC) trial evaluated if Dasatinib (DA) therapy can lead to a successful second treatment-free remission (TFR2) after failing a Imatinib (IM) DISC for first TFR (TFR…
View article: <i>BCR–ABL1</i> transcript doubling time as a predictor for treatment‐free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase
<i>BCR–ABL1</i> transcript doubling time as a predictor for treatment‐free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase Open
Summary The doubling time (DT) of the BCR–ABL1 quantitative polymerase chain reaction (qPCR) transcript level reflects the re‐growing fraction of leukaemic cells after discontinuation of tyrosine kinase inhibitor (TKI). The present study a…
View article: Patient‐reported fatigue refines prognosis in higher‐risk myelodysplastic syndromes (MDS): a MDS‐CAN study
Patient‐reported fatigue refines prognosis in higher‐risk myelodysplastic syndromes (MDS): a MDS‐CAN study Open
Summary The incorporation of patient‐reported outcomes with traditional disease risk classification was found to strengthen survival prediction in patients with myelodysplastic syndromes (MDS). In the present Canadian MDS registry analysis…
View article: Optimal duration of imatinib treatment/deep molecular response for treatment‐free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial
Optimal duration of imatinib treatment/deep molecular response for treatment‐free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial Open
Summary Although total duration of tyrosine kinase inhibitor (TKI) therapy and of molecular response at 4 log reduction or deeper (MR4) correlates with treatment‐free remission (TFR) success after TKI discontinuation, the optimal cut‐off v…
View article: Risk of infection in <scp>MPN</scp> patients in the era of <scp>C</scp>ovid‐<scp>19</scp>: A prospective multicenter study of <scp>257</scp> patients from the <scp>CML‐MPN Q</scp>uebec <scp>R</scp>esearch <scp>G</scp>roup
Risk of infection in <span>MPN</span> patients in the era of <span>C</span>ovid‐<span>19</span>: A prospective multicenter study of <span>257</span> patients from the <span>CML‐MPN Q</span>uebec <span>R</span>esearch <span>G</span>roup Open
Recent studies have disclosed higher rates of infection in patients with the classic Philadelphia-negative myeloproliferative neoplasms (MPN).1-3 Importantly, this increased propensity to infections appears to be inherent to the disease it…
View article: PF410 DOUBLING TIME AFTER FIRST ATTEMPT OF IMATINIB DISCONTINUATION IS HELPFUL TO IDENTIFY THE BEST CANDIDATE FOR THE SECOND ATTEMPT FOR TREATMENT-FREE REMISSION WITH DASATINIB: CANADIAN TRAD TRIAL
PF410 DOUBLING TIME AFTER FIRST ATTEMPT OF IMATINIB DISCONTINUATION IS HELPFUL TO IDENTIFY THE BEST CANDIDATE FOR THE SECOND ATTEMPT FOR TREATMENT-FREE REMISSION WITH DASATINIB: CANADIAN TRAD TRIAL Open
Background: Canadian tyrosine kinase inhibitor (TKI) discontinuation trial is currently ongoing to answer the question if a 2nd generation TKI (2G-TKI), i.e. dasatinib (DA), should be used for retreatment for 2nd attempt of treatment-free …
View article: Molecular monitoring of therapeutic milestones and clinical outcomes in patients with chronic myeloid leukemia
Molecular monitoring of therapeutic milestones and clinical outcomes in patients with chronic myeloid leukemia Open
Background In the current study, the authors determined whether adhering to molecular monitoring guidelines in patients with chronic myeloid leukemia (CML) is associated with major molecular response (MMR) and assessed barriers to adherent…
View article: Overall survival in lower <scp>IPSS</scp> risk <scp>MDS</scp> by receipt of iron chelation therapy, adjusting for patient‐related factors and measuring from time of first red blood cell transfusion dependence: an <scp>MDS</scp>‐<scp>CAN</scp> analysis
Overall survival in lower <span>IPSS</span> risk <span>MDS</span> by receipt of iron chelation therapy, adjusting for patient‐related factors and measuring from time of first red blood cell transfusion dependence: an <span>MDS</span>‐<span>CAN</span> analysis Open
Summary Analyses suggest iron overload in red blood cell ( RBC ) transfusion‐dependent ( TD ) patients with myleodysplastic syndrome ( MDS ) portends inferior overall survival ( OS ) that is attenuated by iron chelation therapy ( ICT ) but…
View article: Early switch to second‐line tyrosine kinase inhibitor in chronic myeloid leukemia patients failing to achieve early molecular response
Early switch to second‐line tyrosine kinase inhibitor in chronic myeloid leukemia patients failing to achieve early molecular response Open
Failure to achieve early molecular response (EMR, BCR-ABL1 copies ≤ 10% by the international scale) 3 months after initiation of tyrosine kinase inhibitor (TKI) therapy has been shown to be a poor prognostic marker in chronic myeloid leuke…
View article: Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia
Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia Open
Treatment of chronic lymphocytic leukemia (CLL) has advanced with the introduction of chemoimmunotherapy (CIT) agents that have improved the outcomes of frontline therapy. However, most treated patients will relapse and require subsequent …